🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Prelude Therapeutics Incorporated

PRLD Healthcare
$4.4 +$0.09 (2.09%)
Market Cap: $442.43 M
Gurus Holding
2
Popularity Rank
#3620
% of Shares Held
0.40%
Net Activity (Q4 2025)
-$634,363

Guru Ownership Trend

Guru Analysis for Prelude Therapeutics Incorporated (PRLD)

Prelude Therapeutics Incorporated (PRLD), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q4 2025, a total of 2 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $1.45 M.

Top institutional holders include Renaissance Technologies (RenTech) and Steven Cohen.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $634,363 net outflow during the quarter.

Recent activity highlights Steven Cohen who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 50.1%.

Key Holders

Top 5 by Value

Top 5 by Conviction

Recent Activity Breakdown (Q4 2025)

+$171,587
Total Buy Value
New Buys 1
Additions 0
-$805,950
Total Sell Value
Reductions 1
Sold Out 1

Guru Consensus (Q4 2025)

Based on recent activity
Net Sellers
2
Net Buyers
1

FAQs for Prelude Therapeutics Incorporated (PRLD)

Major holders include Renaissance Technologies (RenTech) ($786,770), Steven Cohen ($171,587). According to the latest reported data, 2 tracked investment managers collectively hold approximately 330,468 shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $634,363, with 1 managers increasing positions and 2 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited PRLD. The total reported sell value was $805,950.

Yes, 1 managers opened new positions in PRLD, and 0 increased their existing holdings. The total reported buy value was $171,587.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.00% Reduce -50.1% 271,300 $786,770 Q4 2025
0.00% New Buy 59,168 $171,587 Q4 2025
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form